The GARDP Foundation and global biopharmaceutical company Debiopharm have entered a collaboration and license agreement to pursue the development of Debio1453, a novel, first-in-class antibiotic targeting Neisseria gonorrhoeae. This new partnership aims to ensure that gonorrhea continues to be a treatable disease and alleviate the risk of the emergence of future resistance, by ensuring that the antibiotic pipeline continues to be replenished. Gonorrhea caused by N. gonorrhoeae is currently...